Genmab CEO Urges Western Pharma to Leverage Chinese Biotech Innovation

Jan van de Winkel, CEO of one of Europe’s leading biotech companies, Genmab, highlighted the need for Western pharma companies to embrace Chinese biotech innovation, despite growing anti-Chinese sentiment in the US. Following Genmab’s acquisition of US-Chinese drug maker ProfoundBio, van de Winkel noted the rapid growth of Chinese biotech's supported by government funding, which has already attracted the attention of major companies - including AstraZeneca and GSK - who have also made significant deals in China.

For more, please find the original story source here.